RxSight, Inc. (RXST)
NASDAQ: RXST · Real-Time Price · USD
13.75
+0.69 (5.28%)
At close: May 12, 2025, 4:00 PM
14.00
+0.25 (1.82%)
After-hours: May 12, 2025, 5:53 PM EDT

Company Description

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.

It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.

The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017.

RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

RxSight, Inc.
RxSight logo
Country United States
Founded 1997
IPO Date Jul 30, 2021
Industry Medical Devices
Sector Healthcare
Employees 498
CEO Ronald Kurtz

Contact Details

Address:
100 Columbia
Aliso Viejo, California 92656
United States
Phone 949 521 7830
Website rxsight.com

Stock Details

Ticker Symbol RXST
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001111485
CUSIP Number 78349D107
ISIN Number US78349D1072
Employer ID 94-3268801
SIC Code 3851

Key Executives

Name Position
Dr. Ronald M. Kurtz M.D. Co-President, Chief Executive Officer and Director
Eric J. Weinberg Co-President and Chief Commercial Officer
Shelley B. Thunen Co-President and Chief Financial Officer
Dr. Ilya Goldshleger Ph.D. Co-President and Chief Operating Officer
Matt Haller Ph.D. Chief Technology Officer
Oliver Moravcevic Vice President of Investor Relations
Steve Everly Senior Vice President of Sales of North America
Roy Freeman Senior Vice President of Marketing and Professional Relations
Caroline Vaughn Vice President of Human Resources
Scott Gaines Executive Vice President of Manufacturing and Commercial Operations

Latest SEC Filings

Date Type Title
May 7, 2025 10-Q Quarterly Report
May 7, 2025 8-K Current Report
Apr 21, 2025 DEF 14A Other definitive proxy statements
Apr 21, 2025 ARS/A Filing
Apr 21, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 8, 2025 SCHEDULE 13G Filing
Apr 3, 2025 8-K Current Report
Mar 12, 2025 144 Filing
Feb 25, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 25, 2025 10-K Annual Report